News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
308,644 Results
Type
Article (18196)
Company Profile (299)
Press Release (290143)
Multimedia
Podcasts (81)
Webinars (11)
Section
Business (84852)
Career Advice (169)
Deals (14064)
Drug Delivery (47)
Drug Development (55981)
Employer Resources (31)
FDA (6972)
Job Trends (5888)
News (157361)
Policy (11578)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (1071)
Accelerated approval (23)
Adcomms (17)
Allergies (84)
Alliances (23286)
ALS (129)
Alzheimer's disease (1044)
Antibody-drug conjugate (ADC) (304)
Approvals (7201)
Artificial intelligence (298)
Autoimmune disease (117)
Automation (9)
Bankruptcy (113)
Best Places to Work (5242)
BIOSECURE Act (6)
Biosimilars (106)
Biotechnology (230)
Bladder cancer (121)
Brain cancer (52)
Breast cancer (448)
Cancer (3806)
Cardiovascular disease (255)
Career advice (154)
Career pathing (7)
CAR-T (222)
CDC (5)
Cell therapy (585)
Cervical cancer (16)
Clinical research (48221)
Collaboration (1219)
Company closure (2)
Compensation (647)
Complete response letters (43)
COVID-19 (1286)
CRISPR (87)
C-suite (568)
Cystic fibrosis (147)
Data (4667)
Denatured (15)
Depression (94)
Diabetes (264)
Diagnostics (1993)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (197)
Drug pricing (54)
Drug shortages (4)
Duchenne muscular dystrophy (216)
Earnings (33970)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (55287)
Executive appointments (639)
FDA (8882)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (1030)
Gene editing (185)
Generative AI (23)
Gene therapy (502)
GLP-1 (534)
Government (1397)
Grass and pollen (3)
Guidances (182)
Healthcare (7490)
HIV (18)
Huntington's disease (44)
IgA nephropathy (74)
Immunology and inflammation (204)
Immuno-oncology (44)
Indications (77)
Infectious disease (1423)
Inflammatory bowel disease (158)
Inflation Reduction Act (11)
Influenza (48)
Intellectual property (173)
Interviews (18)
IPO (7730)
IRA (15)
Job creations (949)
Job search strategy (136)
JPM (42)
Kidney cancer (10)
Labor market (22)
Layoffs (279)
Leadership (9)
Legal (1641)
Liver cancer (61)
Longevity (11)
Lung cancer (682)
Lymphoma (264)
Machine learning (26)
Management (7)
Manufacturing (390)
MASH (131)
Medical device (3099)
Medtech (3109)
Mergers & acquisitions (6967)
Metabolic disorders (753)
Multiple sclerosis (105)
NASH (13)
Neurodegenerative disease (234)
Neuropsychiatric disorders (70)
Neuroscience (1976)
Neurotech (1)
NextGen: Class of 2026 (2180)
Non-profit (1185)
Now hiring (31)
Obesity (341)
Opinion (131)
Ovarian cancer (144)
Pain (103)
Pancreatic cancer (182)
Parkinson's disease (232)
Partnered (12)
Patents (323)
Patient recruitment (356)
Peanut (44)
People (27768)
Pharmaceutical (44)
Pharmacy benefit managers (7)
Phase 1 (16534)
Phase 2 (22130)
Phase 3 (14765)
Pipeline (3476)
Policy (94)
Postmarket research (1088)
Preclinical (6995)
Press Release (30)
Prostate cancer (160)
Psychedelics (50)
Radiopharmaceuticals (245)
Rare diseases (705)
Real estate (1526)
Recruiting (12)
Regulatory (11176)
Reports (19)
Research institute (1164)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (40)
Schizophrenia (123)
Series A (189)
Series B (146)
Service/supplier (1)
Sickle cell disease (80)
Special edition (18)
Spinal muscular atrophy (120)
Sponsored (16)
Startups (2072)
State (1)
Stomach cancer (10)
Supply chain (34)
Tariffs (19)
The Weekly (65)
Vaccines (397)
Venture capital (71)
Weight loss (187)
Women's health (28)
Worklife (2)
Date
Today (28)
Last 7 days (360)
Last 30 days (1214)
Last 365 days (19080)
2026 (1784)
2025 (19354)
2024 (21960)
2023 (24048)
2022 (28923)
2021 (30011)
2020 (25681)
2019 (17981)
2018 (13153)
2017 (15140)
2016 (13346)
2015 (15959)
2014 (11481)
2013 (8344)
2012 (8392)
2011 (8522)
2010 (8314)
Location
Africa (177)
Alabama (65)
Alaska (2)
Arizona (83)
Arkansas (6)
Asia (19958)
Australia (3437)
California (7492)
Canada (1956)
China (833)
Colorado (259)
Connecticut (286)
Delaware (274)
Europe (43135)
Florida (940)
Georgia (217)
Hawaii (2)
Idaho (18)
Illinois (443)
India (36)
Indiana (182)
Iowa (8)
Japan (268)
Kansas (82)
Kentucky (13)
Louisiana (7)
Maine (11)
Maryland (792)
Massachusetts (5726)
Michigan (113)
Minnesota (268)
Mississippi (3)
Missouri (37)
Montana (16)
Nebraska (6)
Nevada (33)
New Hampshire (23)
New Jersey (1897)
New Mexico (16)
New York (1922)
North Carolina (885)
North Dakota (6)
Northern California (3658)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1339)
Puerto Rico (9)
Rhode Island (25)
South America (237)
South Carolina (9)
Southern California (2982)
Tennessee (43)
Texas (1006)
United States (24876)
Utah (97)
Virginia (139)
Washington D.C. (39)
Washington State (654)
West Virginia (1)
Wisconsin (51)
308,644 Results for "lung therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.
January 13, 2026
·
3 min read
·
Tristan Manalac
Press Releases
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities
January 15, 2026
·
4 min read
Lung cancer
Bayer Wins Lung Cancer Accelerated Approval for Kinase Inhibitor
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 blocker for non-small cell lung cancer.
November 20, 2025
·
1 min read
·
Tristan Manalac
Press Releases
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform
December 1, 2025
·
4 min read
Press Releases
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
February 5, 2026
·
6 min read
Press Releases
Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury
December 16, 2025
·
4 min read
Press Releases
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan’s call to expand equitable access to life-saving early diagnosis
November 12, 2025
·
3 min read
Press Releases
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment
December 3, 2025
·
4 min read
Press Releases
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
January 12, 2026
·
5 min read
Press Releases
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
February 3, 2026
·
8 min read
1 of 30,865
Next
